Cofactor Genomics, a commercial-stage diagnostics company transforming precision oncology through RNA-based predictive tests, today announced strategic investments from Labcorp and Ascension Ventures.

PREDAPT Trial Validates RNA-Based Predictive Biomarker Across 1400+ Patients to Inform Immunotherapy Treatment in NSCLC Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, ...

As part of Y Combinator’s push into computational biology and bioinformatics, the early-stage firm is backing a team that used to work on the Human Genome Project and is now experimenting with RNA ...

Jarret Glasscock, founder and CEO, transitions to Chief Technology Officer (CTO), Board Member, and President ST. LOUIS, January 08, 2025--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a clinical-stage company bridging the precision medicine gap by decoding RNA, announced today the validation and launch of OncoPrism ®-NSCLC, an ...

Cofactor AI, a company that helps hospitals appeal claims denials, announced it raised $4 million in a seed funding round led by Drive Capital. Cofactor AI’s platform, Cofactor Denial Suite, combines ...

Gift Article 10 Remaining As a subscriber, you have 10 articles to gift each month. Gifting allows recipients to access the article for free. Cofactor AI has created software that uses artificial ...

Cofactor Genomics, a leader in cancer immunotherapy predictive diagnostics, today announced results from the PREDAPT non-small cell lung cancer (NSCLC) trial validating the company’s OncoPrism-NSCLC ...

ST. LOUIS--(BUSINESS WIRE)--Cofactor Genomics, Inc., a commercial-stage company bridging the precision medicine gap by decoding RNA, announced that experienced industry leader Chris Parker has been ...